Scarica l'app Stockscreener
0.555
2.21%
0.012
Dopo l'orario di chiusura:
.56
0.005
+0.90%
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics Holds Annual Stockholder Meeting By Investing.com - Investing.com South Africa
Century Therapeutics Holds Annual Stockholder Meeting - Investing.com Australia
Century Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
66,797 Shares in Century Therapeutics, Inc. (NASDAQ:IPSC) Acquired by Two Sigma Investments LP - Defense World
Jane Street Group LLC Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Acquired by Squarepoint Ops LLC - Defense World
Two Sigma Advisers LP Takes $52,000 Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - sharewise
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress - MSN
Deutsche Bank AG Purchases 173,849 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Millennium Management LLC Grows Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Brokers Issue Forecasts for IPSC Q1 Earnings - Defense World
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress - GlobeNewswire
Chardan Capital Issues Optimistic Forecast for IPSC Earnings - Defense World
Leerink Partnrs Has Negative Forecast for IPSC Q2 Earnings - Defense World
Century Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline - MSN
Chardan Trims Price Target on Century Therapeutics to $6 From $7, Maintains Buy Rating - marketscreener.com
Chardan Capital Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $6.00 - Defense World
Chardan Capital Lowers Price Target for Century Therapeutics (IP - GuruFocus
Chardan Capital Lowers Price Target for Century Therapeutics (IPSC) | IPSC Stock News - GuruFocus
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates - sharewise
Century Therapeutics Expands iPSC Cell Therapy to Europe as Q1 Revenue Surges to $109M - Stock Titan
Marshall Wace LLP Purchases New Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Buys 91,468 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
A closer look at Century Therapeutics Inc (IPSC)’s stock price trends - uspostnews.com
Geode Capital Management LLC Acquires 23,413 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Century Therapeutics (IPSC) Expected to Announce Earnings on Thursday - Defense World
An Analysis of Century Therapeutics Inc (IPSC)’s Potential Price Growth - knoxdaily.com
Renaissance Technologies LLC Boosts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Market Insight: Century Therapeutics Inc (IPSC)’s Notable Drop, Closing at 0.50 - DWinneX
Century Therapeutics to Present Preclinical Data at ASGCT 28th Annual Meeting on Novel iPSC-Derived Cell Therapies for Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting - GlobeNewswire
Century Therapeutics Reveals Groundbreaking Cancer-Fighting Cell Therapy Data at Major Scientific Conference - Stock Titan
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Is it possible to buy Century Therapeutics Inc(IPSC) shares at a good price now? - uspostnews.com
Century Therapeutics Inc (IPSC): A Sitting Duck With -825.93% Upside Potential - Stocksregister
H.C. Wainwright maintains Buy rating on Century Therapeutics stock - Investing.com
Century Therapeutics Inc (IPSC)’s financial ratios: A comprehensive overview - DWinneX
H.C. Wainwright maintains Buy rating on Century Therapeutics stock By Investing.com - Investing.com UK
Century Therapeutics Inc [IPSC] Stock sold by Insider Pfeiffenberger Brent for $1375.0 - knoxdaily.com
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):